Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Zollinger-Ellison syndrome (ZES) is characterized by severe peptic disease (ulcers/esophageal disease) caused by hypergastrinemia secondary to a gastrinoma resulting in increased gastric acid secretion.
Biomarker and diagnostic research for Zollinger-Ellison syndrome has been reported in the published literature.
1 FDA-approved treatment is available for Zollinger-Ellison syndrome, including PANTOPRAZOLE SODIUM (PANTOPRAZOLE SODIUM, approved 2017).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Estimated prevalence: 1-9 in 100,000 (Uncommon).
2 clinical trials registered. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
34 publications have been identified in PubMed for Zollinger-Ellison syndrome. Research spans Case Report / Case Series (38%), Review / Meta-Analysis (26%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 13 |
Data assembled from 5 of 12 sources · Last updated Sep 18, 2026, 8:44 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Zollinger-Ellison syndrome
PANTOPRAZOLE SODIUM
PANTOPRAZOLE SODIUM |
— |
2017 |
Available |
PROTONIX DELAYED-RELEASE | PANTOPRAZOLE SODIUM | — | 2007 | Available |
PROTONIX I.V. | PANTOPRAZOLE SODIUM | — | 2001 | Available |
Gene therapy approaches for Zollinger-Ellison syndrome have been reported in the published literature.
2 trials found
Research summaries | 9 | 26% |
Disease patterns and progression | 4 | 12% |
New treatment approaches | 3 | 9% |
Other research | 2 | 6% |
Clinical study results | 2 | 6% |
Testing and diagnosis research | 1 | 3% |
Fernicola A (2026). [PMID: 41585576](https://pubmed.ncbi.nlm.nih.gov/41585576/). *JGH Open*. [Review / Meta-Analysis]
Vanek P (2026). [PMID: 41727390](https://pubmed.ncbi.nlm.nih.gov/41727390/). *VideoGIE*. [Other]
Shah N (2026). [PMID: 30969608](https://pubmed.ncbi.nlm.nih.gov/30969608/). *Unknown Journal*. [Gene Therapy / Novel Therapeutics]
Gaujoux S (2026). [PMID: 41862416](https://pubmed.ncbi.nlm.nih.gov/41862416/). *World J Surg*. [Epidemiology / Natural History]
Carbone F (2026). [PMID: 41997699](https://pubmed.ncbi.nlm.nih.gov/41997699/). *BMJ Open*. [Epidemiology / Natural History]
Romero-Triana D (2026). [PMID: 41577236](https://pubmed.ncbi.nlm.nih.gov/41577236/). *Gastroenterol Hepatol*. [Clinical Trial Publication]
Helbing A (2026). [PMID: 28722872](https://pubmed.ncbi.nlm.nih.gov/28722872/). *Unknown Journal*. [Review / Meta-Analysis]
Ellison EC (2026). [PMID: 41107095](https://pubmed.ncbi.nlm.nih.gov/41107095/). *Am J Surg*. [Other]
Bernshteyn MA (2026). [PMID: 29763120](https://pubmed.ncbi.nlm.nih.gov/29763120/). *Unknown Journal*. [Gene Therapy / Novel Therapeutics]
Rogalidou M (2026). [PMID: 41736231](https://pubmed.ncbi.nlm.nih.gov/41736231/). *Clin Exp Pediatr*. [Review / Meta-Analysis]